Company Filing History:
Years Active: 2020
Title: The Innovations of Tilak K Sundaresan
Introduction
Tilak K Sundaresan is a notable inventor based in Jamaica Plain, MA (US). He has made significant contributions to the field of genetic sequencing, particularly in the development of ultra-sensitive assays for mutation detection. His work is crucial for advancing cancer diagnostics and personalized medicine.
Latest Patents
Tilak holds a patent for "LNA-based mutant enrichment next-generation sequencing assays." This innovative assay is designed for the detection of mutations from blood-based sources of tumor genetic material, such as circulating tumor cells or plasma. It is particularly valuable in scenarios where limited amounts of DNA are available, such as tumor DNA. The assay is exemplified in the estrogen receptor but is broadly customizable to target mutations in other genes. He has 1 patent to his name.
Career Highlights
Tilak K Sundaresan is affiliated with The General Hospital Corporation, where he continues to work on groundbreaking research in genetic sequencing. His expertise in this area has positioned him as a key figure in the development of advanced diagnostic tools.
Collaborations
Throughout his career, Tilak has collaborated with esteemed colleagues, including Zongli Zheng and Daniel Arie Haber. These partnerships have further enhanced the impact of his research and innovations.
Conclusion
Tilak K Sundaresan's contributions to the field of genetic sequencing exemplify the importance of innovation in medical diagnostics. His work not only advances scientific knowledge but also has the potential to improve patient outcomes in cancer treatment.